Sanofi: Berlin Authorised to Grant a Grant to Secure Europe's Supply of Insulin
11 Articles
11 Articles
The European Commission authorises Germany to subsidise the Sanofi pharmaceutical group. The aim is to maintain the group's activity in Europe, in order to secure the European supply of insulin. To guarantee access to this essential medicine in the treatment of diabetes, Berlin releases EUR 400 million.
Here you can find information on the topic "Medicine". Read now "EU approves millions of Sanofi insulin factory in Hesse".
The pharmaceutical company Sanofi is building a new production plant for insulin in Frankfurt. He needs support for this – Germany can now provide it.
The EU Commission has approved aid for a billion-dollar investment in Frankfurt. There is now nothing in the way of the construction of the new Sanofi production facility.
The European Commission has approved a €400 million German state aid program for Sanofi. The program will help the company maintain and expand its insulin production in Germany and secure supplies of the substances needed for its production. The goal is to increase the security of insulin supply for patients in Germany and Europe.
On 8 September 2026, the European Commission authorised German public aid of EUR 400 million for Sanofi-Aventis Deutschland. The aim is to prevent the closure of the Frankfurt-Höchst production site and to strengthen the security of insulin supply in Europe. This decision comes as the European Union seeks to reduce its dependence on insulin. [...] The Sanofi article gets a European green light to secure insulin production in Germany appeared fir…
Coverage Details
Bias Distribution
- 75% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
